SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

11258	Companies
250087	Keywords
178497	Articles
135950	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 07/16/2025 at 07:00, 1 year 3 months ago

Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
Sanofi's SAR446597 receives fast track designation in the US for geographic atrophy due to age-related macular degeneration, aiming to address unmet medical needs with innovative gene therapy

Gene Therapy Sanofi Fast Track Designation Geographic Atrophy SAR446597
PRESS RELEASE

published on 07/15/2025 at 18:30, 1 year 3 months ago

Sanofi: Disclosure of trading in own shares
PRESS RELEASE

published on 06/30/2025 at 21:33, 1 year 4 months ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 06/30/2025 at 07:35, 1 year 4 months ago

Sanofi Releases Q2 2025 Aide Mémoire

Forward-looking Statements Investor Information Financial Modeling Aide Mémoire Sanofi Q2 2025
PRESS RELEASE

published on 06/30/2025 at 07:30, 1 year 4 months ago

Press release: Availability of the Q2 2025 Aide mémoire
Sanofi releases Q2 2025 Aide mémoire for financial modelling, to be published on July 31, 2025. Company details its commitment to innovation and impact in healthcare

Innovation Sanofi Aide Mémoire Financial Modelling Q2 2025
BRIEF

published on 06/25/2025 at 07:05, 1 year 4 months ago

Riliprubart Granted Orphan Drug Designation in the United States

FDA Immunology Orphan Drug Riliprubart Kidney Transplant
PRESS RELEASE

published on 06/25/2025 at 07:00, 1 year 4 months ago

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Sanofi's riliprubart granted orphan drug designation by FDA for antibody-mediated rejection in solid organ transplantation, addressing critical unmet need in transplant medicine

Orphan Drug Designation Sanofi Riliprubart Antibody-mediated Rejection Solid Organ Transplantation
BRIEF

published on 06/23/2025 at 07:05, 1 year 4 months ago

Sarclisa Gains EU Recommendation for Multiple Myeloma Treatment

Multiple Myeloma Phase 3 Study Sarclisa CHMP Approval Induction Therapy
PRESS RELEASE

published on 06/23/2025 at 07:00, 1 year 4 months ago

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by CHMP for transplant-eligible newly diagnosed multiple myeloma based on GMMG-HD7 study. Potential to improve outcomes in frontline setting globally

Multiple Myeloma Sarclisa EU Approval GMMG-HD7 Study CHMP Recommendation
BRIEF

published on 06/20/2025 at 07:05, 1 year 4 months ago

FDA Approves Dupixent for Bullous Pemphigoid Treatment

FDA Approval Dupixent Type 2 Inflammation Bullous Pemphigoid Rare Skin Disease

Accesswire

Published on 11/02/2026 at 17:00, 1 hour 20 minutes ago

PPX Mining Initiates Operating Permit Process for Igor Processing Plant
Published on 11/02/2026 at 17:00, 1 hour 20 minutes ago

QNX Launches Global Developer Hackathon with $50,000 in Prizes to Accelerate Innovation in Mission-Critical Systems
Published on 11/02/2026 at 16:15, 2 hours 5 minutes ago

ACCESS Newswire Launches SPOT, Seven AI Agents That Check Every Press Release Before Submission
Published on 11/02/2026 at 15:00, 3 hours 20 minutes ago

CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)
Published on 11/02/2026 at 14:00, 4 hours 20 minutes ago

GameSquare to Report Q3 2026 Financial Results on November 16, 2026

View all ACCESSWIRE

EQS Group

Published on 11/02/2026 at 18:00, 20 minutes ago

Helvetia Asset Management Ltd adopts a unified market presence
Published on 11/02/2026 at 17:47, 33 minutes ago

Key Figures 31.10.2026
Published on 11/02/2026 at 17:40, 40 minutes ago

VALBIOTIS SA: Valbiotis delivers a first order to its Chinese joint venture and targets a commercial launch in China by the end of 2026
Published on 11/02/2026 at 17:30, 50 minutes ago

GEVELOT S.A.: Weekly declaration of share buybacks – 11/02/2026 (French only)
Published on 11/02/2026 at 16:00, 2 hours 20 minutes ago

Shares Admitted to Trading and Total Voting Rights

Les Echos

Published on 11/02/2026 at 18:00, 20 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 11/02/2026 at 17:59, 21 minutes ago

Saint-Gobain completes the divestment of its Dahl specialist distribution business in Sweden, Norway and Denmark
Published on 11/02/2026 at 17:45, 35 minutes ago

Weekly share buyback
Published on 11/02/2026 at 17:41, 38 minutes ago

Monthly disclosure of the total number of shares and voting rights - October 2026
Published on 11/02/2026 at 15:25, 2 hours 54 minutes ago

Guillemot Corporation S.A. | Information regarding the total number of voting rights and shares 31/10/2026

View all LES ECHOS COMFI WIRE